human renal cell carcinoma rcc cell lines a498  (Procell Inc)

Journal: Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

Article Title: Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal Cell Cancer Cells.

doi: 10.1159/000490140

Figure Lengend Snippet: Fig. 3. Niclosamide effectively inhibits cell cycle progression and induces apoptosis of human RCC cells. (A) Cell cycle analysis. Subconfluent A498 (a) and Caki- 1 (b) cells were treated with Niclosamide or vehicle control for 24h or 48h. Cells were collected, fixed, stained with Hoechst 33258, and subjected to FACS analysis. Percentages of cells in non-G1 phase were tabulated and graphed. Each assay condition was done in triplicate. (B) Exponentially growing A498 and Caki-1 cells were treated with 2μM Niclosamide or DMSO control (0μM). At 72h post treatment, cells were collected, fixed and stained with Hoechst 33258. Apoptotic cells (indicated by yellow arrows) were recorded under a fluorescence microscope (a). Each assay condition was done in triplicate. Apparent apoptotic cells were counted in at least 10 random fields under high-power magnification (b). “**” p< 0.01 (Niclosamide treated vs. control group).

Article Snippet: Materials and Methods Cell Culture and Chemicals Human renal cell carcinoma (RCC) lines A498 and Caki-1 were purchased from ATCC (Manassas, VA) and maintained in complete Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% fetal bovine serum (FBS, Invitrogen, Carlsbad, CA), 100 units of penicillin and 100μg of streptomycin at 37°Cin 5% CO2 [40-42].

Techniques: Cell Cycle Assay, Control, Staining, Fluorescence, Microscopy

Journal: Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

Article Title: Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal Cell Cancer Cells.

doi: 10.1159/000490140

Figure Lengend Snippet: Fig. 5. Niclosamide synergizes with sorafenib in inhibiting the proliferation of human RCC cells. Exponentially growing A498 (A) and Caki-1 (B) cells were seeded in 12-well cell culture plates and treated with the indicated concentrations of niclosamide or sorafenib (SOR), or with varied concentrations of niclosamide at the 10µM sorafenib. At 72h post treatment, the viable cells were fixed and stained with Crystal violet. Each assay condition was done in triplicate. Representative results are shown.

Article Snippet: Materials and Methods Cell Culture and Chemicals Human renal cell carcinoma (RCC) lines A498 and Caki-1 were purchased from ATCC (Manassas, VA) and maintained in complete Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% fetal bovine serum (FBS, Invitrogen, Carlsbad, CA), 100 units of penicillin and 100μg of streptomycin at 37°Cin 5% CO2 [40-42].

Techniques: Cell Culture, Staining